All In Biotech

Drug Trial Radar · NCT04887831

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)

Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

92

Actual

Start

Jun 4, 2021

Primary completion

Apr 7, 2023

Study completion Mar 1, 2024

Sponsor

Lead sponsor
G1 Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in participants receiving first-line treatment for advanced/metastatic urothelial carcinoma.

Conditions

  • Urothelial Carcinoma
  • Bladder Cancer
  • Myelosuppression Adult
  • Chemotherapy-induced Neutropenia
  • Metastatic Bladder Cancer

Interventions

  • TrilaciclibDrug

    Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.

  • GemcitabineDrug

    Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle

  • CisplatinDrug

    Cisplatin administered IV on Day 1 of each 21-day cycle

  • CarboplatinDrug

    Carboplatin administered IV on Day 1 of each 21-day cycle

  • AvelumabDrug

    Avelumab administered IV on Day 1 of each 14-day maintenance cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Progression-Free Survival (PFS) During Overall StudyTime frame: From date of randomization until date of documented radiologic disease progression per RECIST v1.1 or death due to any cause, whichever comes first. Approximately 96 weeks

Locations

34 sites in 5 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trial

    Los Angeles, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • Rocky Mountain Cancer Centers

    Littleton, Colorado

  • Florida Cancer Specialists - South

    Fort Myers, Florida

  • Woodlands Medical Specialists

    Pensacola, Florida

  • Florida Cancer Specialists - North

    St. Petersburg, Florida

  • Beacon Cancer Center PLLC

    Coeur d'Alene, Idaho

  • The Harry and Jeanette Weinberg Cancer Institute

    Baltimore, Maryland

  • New York Oncology Hematology, P.C.

    Albany, New York

  • Montefiore Medical Center

    The Bronx, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Northwest Cancer Specialists, P.C.

    Tigard, Oregon

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Centre Léon Bérard - Département d'oncologie médicale

    Lyon, France

  • Hôpital Européen Georges Pompidou - Service d'Oncologie Médicale

    Paris, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France

  • Hopitaux Universitaires de Strasbourg - Service Oncologie et Hématologie

    Strasbourg, Bas-Rhin, France

  • Institut Bergonié - Oncologie Médicale et Pédiatrique

    Bordeaux, Gironde, France

  • National Center of Urology Named after Laur Managadze

    Tbilisi, Georgia

  • LTD "Multiprofile Clinic Consilium Medulla"

    Tbilisi, Georgia

  • High Technology Hospital MedCenter LTD

    Batumi, Adjara, Georgia

  • Országos Onkológiai Intézet

    Budapest, Hungary

  • Uzsoki Utcai Kórház

    Budapest, Hungary

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendeloint

    Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Hospital Universitario Vall d´Hebron

    Barcelona, Spain

  • Hospital Clinic de Barcelona - Servicio de Oncología Médica

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • H.U. V. de las Nieves

    Granada, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Spain

  • Fundación Instituto Valenciano de Oncología

    Valencia, Spain

  • Hospital Politecnic Universitari La Fe

    Valencia, Spain

  • Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • ALTHAIA, Xarxa Assistencial Universitiria de Manresa

    Manresa, Barcelona, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.